NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)

CompletedN/A

Sponsor: Pfizer

Conditions: Carcinoma, Renal Cell

Interventions: sunitinib malate

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

Eligibility overview

Sex: ALL

Age: 0 Days to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients need to be administered sunitinib malate (Sutent) in order to be enrolled in the surveillance.

Exclusion Criteria:

* Patients not administered sunitinib malate (Sutent).